These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38822123)

  • 21. Visual disturbance or central symptom like hallucination in patients treated voriconazole: report of six cases.
    Kato H; Hagihara M; Hamada Y; Koizumi Y; Nishiyama N; Yamagishi Y; Matsuura K; Mikamo H
    Jpn J Antibiot; 2016 Sep; 69(3):143-150. PubMed ID: 30226950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.
    Yin G; Song G; Xue S; Liu F
    Sci Rep; 2024 May; 14(1):11367. PubMed ID: 38762547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Publicity and reports of behavioral addictions associated with dopamine agonists.
    Gendreau KE; Potenza MN
    J Behav Addict; 2016 Mar; 5(1):140-143. PubMed ID: 26690325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D
    Hopkins SC; Ogirala A; Zeni C; Worden M; Koblan KS
    Clin Drug Investig; 2022 Dec; 42(12):1113-1121. PubMed ID: 36350559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline.
    Kamakura K; Mochizuki H; Kaida K; Hirata A; Kanzaki M; Masaki T; Nakamura R; Motoyoshi K
    Parkinsonism Relat Disord; 2004 Jun; 10(4):235-42. PubMed ID: 15120098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Occurrence of voriconazole-induced cutaneous squamous cell carcinoma in Japan: data mining from different national pharmacovigilance databases.
    Tanaka H; Okuma M; Ishii T
    Pharmazie; 2022 Oct; 77(10):307-310. PubMed ID: 36273254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease.
    Makoff AJ; Graham JM; Arranz MJ; Forsyth J; Li T; Aitchison KJ; Shaikh S; Grünewald RA
    Pharmacogenetics; 2000 Feb; 10(1):43-8. PubMed ID: 10739171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
    Wittayanukorn S; Qian J; Johnson BS; Hansen RA
    J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database.
    Kazerooni R; Armstrong EP
    Clin Drug Investig; 2018 Sep; 38(9):867-872. PubMed ID: 29926379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
    Sato K; Mano T; Iwata A; Toda T
    Biosci Trends; 2020 May; 14(2):139-143. PubMed ID: 32321905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
    Kitagawa M; Tashiro K
    Intern Med; 2005 Sep; 44(9):939-43. PubMed ID: 16258207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
    Szarfman A; Tonning JM; Levine JG; Doraiswamy PM
    Pharmacotherapy; 2006 Jun; 26(6):748-58. PubMed ID: 16716128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
    Liu L; Chen J; Wang L; Chen C; Chen L
    Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Psychiatric manifestations induced by dopamine precursors or antagonists].
    Leger JM; Dumond JJ; Garoux R; Lombertie E; Dumas M
    Ann Med Psychol (Paris); 1979 Nov; 137(9):899-908. PubMed ID: 398173
    [No Abstract]   [Full Text] [Related]  

  • 35. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.
    Hu Y; Bai Z; Tang Y; Liu R; Zhao B; Gong J; Mei D
    J Diabetes Res; 2020; 2020():3695101. PubMed ID: 32695827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease.
    Schumacher-Schuh AF; Francisconi C; Altmann V; Monte TL; Callegari-Jacques SM; Rieder CR; Hutz MH
    Int J Neuropsychopharmacol; 2013 Jul; 16(6):1251-1258. PubMed ID: 23363854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).
    Huang J; Zhao Y; Cao Y; Zhang Q; Ran D; Li J; Luo L; Qiu F; Meng L
    Int J Clin Pharm; 2022 Aug; 44(4):993-1003. PubMed ID: 35776375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
    Huang J; Cai J; Ye Q; Jiang Q; Lin H; Wu L
    BMJ Open; 2023 Aug; 13(8):e071456. PubMed ID: 37536976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
    Raschi E; Girardi A; Poluzzi E; Forcesi E; Menniti-Ippolito F; Mazzanti G; De Ponti F
    Drug Saf; 2018 Aug; 41(8):745-752. PubMed ID: 29582393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.